	US 12,325,751 B2
	Anti-CD25 antibody and application thereof
Deyong Song, Shandong (CN); Xiu Liu, Shandong (CN); and Jing Han, Shandong (CN)
Assigned to Shandong Boan Biotechnology Co., Ltd., Yantai (CN)
Appl. No. 17/601,321
Filed by Shandong Boan Biotechnology Co., Ltd., Shandong (CN)
PCT Filed Jun. 8, 2020, PCT No. PCT/CN2020/094919 § 371(c)(1), (2) Date Oct. 4, 2021, PCT Pub. No. WO2020/248938, PCT Pub. Date Dec. 17, 2020.
Claims priority of application No. 201910495614.4 (CN), filed on Jun. 10, 2019; and application No. 201910495626.7 (CN), filed on Jun. 10, 2019.
Prior Publication US 2022/0195055 A1, Jun. 23, 2022
Int. Cl. A61K 39/395 (2006.01); C07K 16/28 (2006.01); C12N 15/13 (2006.01); G01N 33/574 (2006.01); G01N 33/577 (2006.01)

CPC C07K 16/2866 (2013.01) [G01N 33/574 (2013.01); G01N 33/577 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01)]

14 Claims

1. An antibody or antigen-binding fragment thereof that binds to CD25, comprising three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3), wherein HCDR1 comprises SEQ ID NO: 14, HCDR2 comprises SEQ ID NO: 15, and HCDR3 comprises SEQ ID NO: 16; and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3), wherein LCDR1 comprises SEQ ID NO: 11, LCDR2 comprises SEQ ID NO: 12, and LCDR3 comprises SEQ ID NO: 13.